China Animal Husbandry Industry Co., Ltd.: history, ownership, mission, how it works & makes money

Founded on December 25, 1998 and listed on the Shanghai Stock Exchange as 600195 on January 7, 1999, China Animal Husbandry Industry Co., Ltd. (CAHIC) is the animal husbandry arm of the state-owned China National Agricultural Development Group under SASAC, offering more than 800 products-from veterinary vaccines and feed premixes to quinocetone and tiamulin-used in nearly 60 countries and driving prevention of major animal diseases and food security; the company reported 6.02 billion CNY revenue in 2024 (up 11.30% YoY) with 4,299 employees, posted H1 2025 revenue of 2.793 billion CNY (+12.63%) and net profit attributable to shareholders of 81.762 million CNY (+30.19%), has invested 10.419 billion CNY in R&D over the past three years, holds industry-leading market shares across key product lines, operates through four core segments (Animal Disease Prevention, Treatment, Nutrition and Others), maintains over 20 subsidiaries and an extensive distribution network, and-while remaining publicly traded-expanded strategic investments in 2025 including a 241.42 million CNY subscription to Gindalbie convertible bonds, signaling a blend of state-backed scale, innovation-driven R&D and diversified revenue streams that merit a closer look into its history, ownership, operations and financial model.

China Animal Husbandry Industry Co., Ltd. (600195.SS): Intro

• Founding date: December 25, 1998
• SSE listing: January 7, 1999 (600195.SS)
• Parent: China National Agricultural Development Group Corporation
• Employees (2024): 4,299 (down 0.62% YoY)

Business scope and products

• Total SKUs: >800 products
• Key product categories:
  • Veterinary vaccines
  • Multivitamin additives and feed premixes
  • Antibiotic/antimicrobial agents (e.g., tiamulin, bambermycin, quinocetone)
• Market reach: products used in nearly 60 countries and regions
• Role: prevention/control of major animal diseases and support for food security in husbandry

Ownership & corporate structure

• Major shareholder: China National Agricultural Development Group Corporation (state-owned group)
• Listed public company on Shanghai Stock Exchange (ticker 600195)
• Operational structure: R&D, manufacturing, distribution and international trade divisions focused on veterinary pharmaceuticals and feed additives

Financial snapshot (2022-2024)

Where prior-year raw figures are not published here, indicated cells show reference or are omitted; 2024 figures are company-reported.

How it works - value chain and revenue drivers

• R&D and regulatory approval: invests in vaccine and drug development; maintains production licenses and quality systems to comply with Chinese and export regulations.
• Manufacturing: operates production lines for vaccines, feed premixes and active compounds; scales via centralized plants and toll manufacturing partners.
• Distribution and sales: multi-channel distribution covering domestic veterinary clinics, large integrators (poultry, swine), feed mills, and export partners across ~60 markets.
• Revenue streams:
  • Product sales - veterinary vaccines, antibiotics, feed additives (principal)
  • OEM and contract manufacturing
  • Export sales to international distributors and integrators
• Market advantages: broad product portfolio (>800 SKUs), leading domestic market shares for selected vaccine and additive categories, parent-group support for procurement and policy alignment.

Market position and international reach

• Leading positions in multiple domestic segments such as veterinary vaccines and selected feed additives (e.g., tiamulin, bambermycin).
• Export footprint: products used in nearly 60 countries/regions, supporting disease control programs abroad.
• Strategic importance: contributes to national food security by supporting livestock health and reducing outbreak risk.

More detailed company history, ownership structure, mission and monetization mechanics can be found at: China Animal Husbandry Industry Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

China Animal Husbandry Industry Co., Ltd. (600195.SS): History

• Parent ownership: China National Agricultural Development Group Corporation (state-owned), under the State-owned Assets Supervision and Administration Commission (SASAC).
• Listing: Shanghai Stock Exchange, ticker 600195.SS.
• Shareholder base: mix of institutional and retail investors; public float alongside state ownership.
• Recent strategic investment: August 2025 preferential subscription for Gindalbie convertible bonds - up to 241.42 million CNY committed.

China Animal Husbandry Industry Co., Ltd. (600195.SS): Ownership Structure

• Provide high-quality animal health and nutrition products to ensure the safety and security of animal husbandry nationwide and abroad.
• Emphasize technological innovation - operating a National Enterprise Technology Center approved by five ministries and commissions, focused on animal nutrition, breeding, health care and automated farming facilities.
• Commit to environmental sustainability and development of a green, healthy aquatic and livestock industrial chain to meet rising consumer demand for safe food.
• Value global collaboration: products marketed and used in nearly 60 countries, supporting healthier husbandry practices worldwide.
• Strive to be a world-class safe food supplier and a world-class clean energy operator, in line with China's National Agricultural Industrialization Initiative.
• Uphold integrity, quality and customer-centricity as core principles guiding operations and strategic decisions.

• Core revenue streams: animal nutrition (feed additives, premixes), veterinary drugs and health products, breeding services and integrated farm solutions (automation, waste treatment).
• Value chain integration: R&D → production → distribution → farm-level service contracts; premium solutions (biosecurity, feed formulation) command higher margins.
• Scale and exports: leveraging manufacturing scale and export channels to sell into nearly 60 countries, diversifying currency and market risk.
• R&D-driven product pipeline: technology center supports proprietary formulations and farm automation products that extend product lifecycles and margin protection.

• State-related and institutional shareholders hold the controlling blocks typical for large Chinese agricultural industrial groups, providing strategic stability and policy alignment.
• Public float on the Shanghai Stock Exchange enables retail and institutional investors to participate in operational growth and export expansion.

China Animal Husbandry Industry Co., Ltd. (600195.SS): Mission and Values

• Operating segments: Animal Disease Prevention, Animal Disease Treatment, Animal Nutrition, and Others, each delivering specialized products and services across the livestock, poultry, and companion-animal value chains.
• Product breadth: biological products and veterinary vaccines, veterinary drug formulations, medicated and non‑medicated animal feed, feed raw materials and additives, and related farm equipment and services.
• Distribution and reach: more than 20 wholly‑owned or partly‑owned subsidiaries underpin an extensive domestic and international distribution network covering manufacturing, cold‑chain logistics for biologics, regional sales, and technical service teams.

• R&D intensity: CAHIC invested over 10.419 billion CNY in the latest three years, funding vaccine development, novel therapeutics, nutritional formulations and scale‑up of production lines. This investment has produced multiple market‑applicable achievements and pipeline candidates for commercialization.
• National Enterprise Technology Center: central hub for innovation, with focus areas including animal nutrition optimization, breeding technologies, preventive healthcare, and automated farming facilities to raise productivity and biosecurity.
• Supply chain robustness: integrated manufacturing sites, quality control labs, cold‑chain capabilities for biologics, and regional distribution centers to ensure timely production and delivery across China and export markets.
• Subsidiary network: over 20 subsidiaries provide local market penetration, manufacturing diversification, and specialized R&D/production capabilities, reducing single‑site risk and improving responsiveness to demand shifts.

• Manufacturing footprint: multiple production bases for vaccines, drugs and feeds to match regional demand and maintain supply continuity.
• Quality and regulatory compliance: adherence to national veterinary regulatory standards and international GMP/quality practices for biologics and drugs.
• Revenue mix: diversified across prevention (vaccines/biologics), treatment (drugs), and nutrition (feeds), reducing exposure to single-market volatility.
• International expansion: exports and overseas partnerships supported by subsidiary network and targeted international sales channels.

• 10.419 billion CNY R&D investment over the past three years fueling product launches, manufacturing upgrades, and platform technologies (vaccine platforms, feed additive technologies, diagnostic kits).
• National Enterprise Technology Center's projects include nutritional optimization trials, breeding-health integration pilots, and automation solutions for large-scale farms-each designed to shorten time-to-market for applied innovations.

• Scale in high-volume feed and vaccine production to capture cost advantages and stable cash flows.
• Proprietary or differentiated drug formulations and vaccines to achieve higher gross margins and defend market share.
• After‑sales services, technical support and equipment sales (Others) to deepen customer relationships and generate recurring service revenues.
• Continued R&D investment to replenish product pipelines and respond to regulatory or epidemiological shifts that create new demand.

China Animal Husbandry Industry Co., Ltd. (600195.SS): How It Works

• Primary revenue segments: Animal Disease Prevention, Animal Disease Treatment, Animal Nutrition, and Others (including raw material trading and ancillary services).
• Product lines: veterinary vaccines, multivitamin additives, feed premixes, veterinary drugs, lysins and other bioactive agents.
• Market coverage: domestic sales across China and international exports of vaccines, feed additives and pharmaceutical products.

• Sales of veterinary vaccines and disease-prevention products to large-scale farms, distributors and government procurement channels.
• Sales of animal disease treatment drugs (therapeutics and antimicrobials) to veterinary clinics, integrators and agricultural enterprises.
• Sales of animal nutrition products-multivitamin additives, feed premixes and fortified feed components-to feed mills and integrators.
• Raw material trading (corn, soybean meal, fish meal) and specialty ingredients such as lysins-trading and spot sales contribute to commodity income and inventory optimization.
• Strategic financial investments (e.g., participation in convertible bonds such as those of Gindalbie) and minority holdings that provide investment income and portfolio diversification.
• Technology licensing, contract research, and co-development projects that monetize R&D and accelerate product rollouts.

• Animal Disease Prevention: recurring sales of vaccines and immunogens; high-margin product line that benefits from herd immunization programs.
• Animal Disease Treatment: commodity and specialized pharmaceuticals-volume-driven with periodic spikes during disease outbreaks.
• Animal Nutrition: steady, contract-based sales of premixes and additives tied to feed demand and livestock population trends.
• Others (including raw material trading): contributes cash-flow flexibility-corn, soybean meal and fish meal trading smooths margins across feed cycles.

• R&D and product innovation: development of new vaccines, lysin-based alternatives and optimized premixes to command premium pricing and expand addressable markets.
• Vertical integration and supply chain optimization: raw material sourcing, in-house formulation and distribution efficiencies reduce COGS and inventory risk.
• Export growth and international registration of core vaccines/drugs: opens higher-margin markets and diversifies revenue base.
• Strategic investments and financial assets: convertible bonds and minority stakes that provide non-operating income and balance-sheet flexibility.

China Animal Husbandry Industry Co., Ltd. (600195.SS): How It Makes Money

• Core product lines: veterinary vaccines, multivitamin additives, feed premixes, quinocetone, bambermycin, tiamulin - areas where CAHIC holds industry-leading market share.
• Geographic reach: products sold in nearly 60 countries and regions, supporting disease prevention, animal health programs and food security globally.
• Revenue drivers: sales of proprietary vaccines and additives, large-scale supply contracts with integrators and distributors, R&D-driven premium products, and licensing/technology transfer agreements.

• How revenue mix works: recurring sales from feed premixes/additives and bulk API supply provide steady cashflows; higher-margin vaccine and proprietary biotech products drive margin expansion.
• Commercial channels: direct sales to large livestock integrators, distributors, export partners, and government/public health tenders for disease control programs.
• Future expansion levers: targeted R&D, vertical integration of value chain, international market penetration, and strategic investments in adjacent industries (including high-purity polysilicon, solar cells and aquatic feed as part of portfolio diversification).